PublisherBMJ Publishing Group
MetadataShow full item record
DescriptionSubtitle: Why they must help us improve the evidence base; Editorial in which the authors discuss drug clinical trial data submitted to the US Food and Drug Administration and call for regulators to correct misleading information published in the medical literature.
CitationDoshi, P. & Godlee, F. (2017). The wider role of regulatory scientists. BMJ, 357. DOI: 10.1136/bmj.j1991
Keywordethical responsibility of regulatory scientists
Access to Information
Clinical Trials as Topic
United States. Food and Drug Administration--ethics
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/6593
- Some key points emerging from the COX-2 controversy.
- Authors: Urquhart J
- Issue date: 2005 Mar
- [Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro].
- Authors: Zhu FS, Chen XM, Wang YJ, Zhang X, Feng JX
- Issue date: 2007 Mar
- Precautionary harm disclosure in clinical trials.
- Authors: Wu KC
- Issue date: 2009 Aug
- Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2.
- Authors: Fries S, Grosser T, Price TS, Lawson JA, Kapoor S, DeMarco S, Pletcher MT, Wiltshire T, FitzGerald GA
- Issue date: 2006 Jan
- FDA approval of paroxetine for menopausal hot flushes.
- Authors: Orleans RJ, Li L, Kim MJ, Guo J, Sobhan M, Soule L, Joffe HV
- Issue date: 2014 May 8